The Next Big Theme: July 2023

Tesla remains the market leader despite EV industry speed up, Meta’s ‘Threads’ breaks record with blazing launch, and Asia’s semiconductor dominance stands strong despite geopolitical concerns. In this month’s Next Big Theme, Global X explores the investment outlook for thematics such as EV adoption, social media, cloud computing, and more.

Electric Vehicles

EVs and Battery Markets Speed Up in First Half

Despite traditional automakers making progress, Tesla widened its lead as the top U.S. electric vehicle (EV) seller. In the first half of the year, Tesla sold roughly 300,000 more units than each of its closest competitors, Hyundai Motor and General Motors. For the same period in 2022, the unit gap was 225,000.1 Tesla’s sales increased an estimated 30% to 336,892 in the first half of the year (H1).2 General Motors quadrupled its electric car and truck sales to 36,322 units through June, while Volkswagen more than doubled its EV sales to 26,538 units.3 Advancements by key players like Stellantis, which introduced its STLA Medium platform, contributed to EV market growth. This platform supports multiple propulsion configurations and offers a standard range of over 500 kilometres, extendable up to 700 kilometres with a performance pack.4

The global battery demand for EVs is expected to increase from 509 gigawatt hours (GWh) in 2022 to 3,295GWh in 2030.5 Government mandates such as China’s extension of tax exemptions for new energy vehicles (NEVs) until 2027 is helping adoption.6 Currently, Chinese consumers can benefit from EV tax breaks starting at over US$4,000 per vehicle, before the incentives gradually decline over the next four years.7

Social Media & Millennial Consumers

Threads Ties Younger Generations Together

Instagram’s new conversation-based Threads app garnered 2 million users within its first two hours and over 100 million users in a matter of days after its launch.8 Not only are users signing up for Threads, but they are also actively engaging with the app. Within the first day, there were more than 95 million posts and 190 million likes shared on the platform.9 Parent company Meta is excited about the successful launch, but management emphasised the need to assess user retention. Threads debuts at an opportune time with younger consumers increasingly relying on social media for guidance. A recent study found that 46% of Millennials seek restaurant information from eateries’ social media pages, followed closely by 42% of Gen Z consumers.10 For Gen Z, influencer recommendations and brand-sponsored content heavily influence their clothing purchases. One in three participants in a recent study cited recommendations from influencers as motivators to purchase from a new brand, while one in five said brand-sponsored content works.11

Cloud Computing & Artificial Intelligence

Generative AI and Hybrid Cloud Models

The rising popularity of hybrid cloud infrastructure, which integrates components of public cloud, private cloud, and on-premises infrastructure into a cohesive architecture, has companies expanding their business models. IBM announced a definitive agreement with Vista Equity Partners to acquire Apptio Inc. for US$4.6 billion.12 Apptio, which provides financial and operational IT management and optimisation (FinOps) software, can help accelerate IBM’s IT automation capabilities, allowing enterprise leaders to maximise the value derived from their technology investments.13 Apptio’s product lineup, including ApptioOne and Apptio Cloudability, includes features for managing and optimising hybrid and public cloud expenditures.

In 2022, global revenue from public cloud services surpassed US$500 billion, a significant milestone, and generative AI sets up to be a key catalyst for future growth in public cloud spending.14 In response, Amazon Web Services (AWS) committed a substantial US$100 million investment towards a new generative AI program. Named the AWS Generative AI Innovation Centre, the program aims to help customers develop and deploy generative AI solutions.15 As of now, Oracle’s Gen2 Cloud has emerged as the leading choice for running generative AI workloads, attesting to its mounting success as a provider.16

Semiconductors & Data Centres

Asia Shows Its Semiconductor Dominance

Taiwan Semiconductor Manufacturing Corp.’s (TSMC) sales surged during the second quarter amid surging demand for AI applications and the company’s chipmaking prowess.17 TSMC is the primary contract manufacturer for Nvidia’s AI accelerator chips used to train large data models such as OpenAI’s ChatGPT.18 Japan’s government-backed fund, Japanese Investment Corp., proposed an acquisition of semiconductor materials giant JSR worth 903.9 billion yen (US$6.3 billion).19 Japan is focusing on its traditional strengths, particularly companies like JSR, which specialises in chemicals and materials. Similarly, South Korea leads the memory chip market, which combined with its robust AI ecosystem, gives it an edge in the global AI chip race. Samsung Electronics and SK Hynix, two of the world’s largest dynamic random-access memory chipmakers, are investing in AI research and development. Samsung plans to invest 300 trillion Korean won (US$228 billion) in a new semiconductor facility in South Korea.20 With its digital strategy, South Korea aims to be one of the world’s top three AI markets by 2027, closely trailing the U.S. and China.21


Pharmaceutical Deals and Approvals

Moderna secured a US$1 billion deal to advance messenger RNA (mRNA) medicine research, development, and manufacturing in China.22 The deal represents another step towards Moderna’s goal of ramping up investments in Shanghai and forming partnerships with Chinese counterparts. In May, the company established the Moderna Biotech China unit in Shanghai. In the United States, two major pharmaceuticals achieved major milestones. Sarepta Therapeutics obtained accelerated Food and Drug Administration (FDA) approval for ELEVIDYS, an adeno-associated virus-based gene therapy for Duchenne muscular dystrophy (DMD). The therapy is for ambulatory paediatric patients, 4–5 years old, with a confirmed DMD gene mutation.23 Also, the FDA cleared BioMarin’s Roctavian as a one-time therapy for severe haemophilia A. The FDA-approved label for Roctavian highlights the phase 3 GENEr8-1 trial results. For 112 patients who received the gene therapy, bleeding cases per year declined by an average of 52% over a median three years of follow-up.24